Options with increasing volume: BYD LLY VRX CELG URBN CTRP HPQ DE GME MU
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM ESTLeerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.
Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM ESTBMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).
Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More
